Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO RESPICLICK versus ARMONAIR RESPICLICK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO RESPICLICK versus ARMONAIR RESPICLICK.
AIRDUO RESPICLICK vs ARMONAIR RESPICLICK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone propionate (corticosteroid) and salmeterol (long-acting beta2-adrenergic agonist); fluticasone reduces inflammation via glucocorticoid receptor activation, salmeterol relaxes bronchial smooth muscle via beta2-receptor stimulation.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Two inhalations (55 mcg/113 mcg per inhalation) twice daily via oral inhalation; maximum 2 inhalations twice daily. For patients with asthma, starting dose is one inhalation twice daily; may increase to two inhalations twice daily after 1-2 weeks if inadequate response.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
None Documented
None Documented
Salmeterol: terminal elimination half-life of 5.5 hours. Fluticasone furoate: terminal elimination half-life of approximately 24 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Renal elimination of salmeterol: approximately 25% of dose excreted unchanged in urine. Fluticasone furoate: primarily excreted as metabolites in feces (≥90%) following intravenous administration, with less than 5% excreted in urine.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Category C
Category C
Inhaled Corticosteroid/LABA Combination
Inhaled Corticosteroid